Amedica stock has upside potential ahead of releasing its first quarter financial statement, according to a Seeking Alpha report.
Here are eight key notes on the company:
1. Amedica's silicon nitride implants have been growing 40 percent per year because implant properties are showing positive results.
2. The company expects to receive FDA clearance for the CASCADE device after a successful study showed good outcomes.
3. The company's reorganization is expected to save $6 million to $8 million per year beginning this year.
4. Surgeons are interested in the silicon nitride technology and learning more about its implants. There are currently 20,000 of Amedica's silicon nitride spine products implanted in patients.
5. Amedica branched out from silicon nitride products to also include other fusion products designed to treat deformity and degenerative spine procedures.
6. Although t he company's stock price has slid in 2015 due to warrant conversions related to two dilutive financing agreements, the adverse effects of the warrant conversions will probably end in the near future.
7. Last month, Amedica CEO reiterated the company's 2015 guidance, which includes a 30 percent to 40 percent increase in the silicon nitride revenues, a 12 percent year-over-year revenue growth. Amedica will release their first quarter financial report later this week.
8. The benefits of OEM agreements with Spinal Kinetics and Kyocera will also begin to "bear fruit" in the near future.